# Gasdermin E-mediated pyroptosis in promoting antitumor immunity and cancer treatment > **NIH NIH K99** · BOSTON CHILDREN'S HOSPITAL · 2022 · $112,242 ## Abstract Project Summary/Abstract The majority of cancers, which are immunologically “cold” with limited T cell infiltration, show abysmal response rates to immunotherapy. Novel strategies to enhance recruitment and functions of tumor-infiltrating lymphocytes (TIL) are urgently needed to improve cancer immunotherapy. How cancer cells die in response to stress, cytotoxic lymphocytes, and drugs has a profound impact on the immune landscape of cancer. While most cancer cell death has been viewed as noninflammatory, our recent study showed that pore-forming protein Gasdermin E (GSDME), when expressed in tumor cells, converts noninflammatory apoptosis to pyroptosis, a highly inflammatory form of programmed cell death. GSDME potently inhibits tumor growth and enhances the numbers and antitumor functions of CD8+ and NK TILs. The tumor-inhibitory effect of GSDME is mediated by TIL killing of GSDME+ target tumor cells, which can also trigger tumor cell pyroptosis. Our study suggests that promoting cancer cell pyroptosis has excellent potential to improve cancer immunotherapy, but it remains unclear how GSDME-induced pyroptosis boosts antitumor immunity. The proposed research aims to investigate how tumor GSDME expression shapes the tumor-infiltrating immune cells and their interactions to increase tumor immunity, and to develop a novel strategy to promote inflammatory cancer cell death, with the long-term goal to enhance immunotherapeutic efficacy for cancer patients. Specifically, I will study how damage-associated molecular patterns (DAMPs) produced by GSDME+ tumor cells modulate the composition, maturation, and functions of tumor-infiltrating dendritic cells (TIDCs) and tumor-associated macrophages (TAMs), key players to induce potent antitumor T cell response, by using CyTOF and inhibitors of DAMPs or their receptors (Aim 1). Aided by single cell (sc)RNA-seq and bone marrow chimeric mice, I will study how different TIDC subsets interact with CD8+ TILs to promote GSDME-mediated antitumor immunity (Aim 2). As many cancer cells epigenetically silence GSDME and RIPK3 (key mediator of necroptosis, another inflammatory form of cell death) via promoter hypermethylation, I will investigate whether the DNA methylation inhibitor decitabine could promote cancer cell pyroptosis and necroptosis to suppress tumor growth and enhance antitumor immunity (Aim 3). These studies will greatly advance our understanding of GSDME’s immunostimulatory mechanism and offer new opportunities to revitalizing immunotherapeutic efficacy for patients with uninflamed “cold” tumors. My career goal is to lead an independent academic laboratory addressing questions on cancer immunology and immunotherapy. In the K99 phase, I will take full advantage of the extensive resources at the vibrant research community of Harvard and the outstanding team of mentors and collaborators to receive comprehensive training in advanced technologies, bioinformatics, mouse models, and translational research, to furth... ## Key facts - **NIH application ID:** 10338167 - **Project number:** 5K99CA255841-02 - **Recipient organization:** BOSTON CHILDREN'S HOSPITAL - **Principal Investigator:** Ying Zhang - **Activity code:** K99 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2022 - **Award amount:** $112,242 - **Award type:** 5 - **Project period:** 2021-02-01 → 2022-06-30 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10338167 ## Citation > US National Institutes of Health, RePORTER application 10338167, Gasdermin E-mediated pyroptosis in promoting antitumor immunity and cancer treatment (5K99CA255841-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10338167. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*